Lakewood-Amedex Biotherapeutics

Overview

Lakewood-Amedex Biotherapeutics, based in Sarasota, Florida, focuses on anti-infective drug development for indications where standard-of-care antibiotics are failing. Steven J. Parkinson, a veteran of drug development and licensing, has led the company as President and CEO through preclinical and early clinical-phase work on its bisphosphocin platform. Taffy Williams, the CFO, provides operational leadership and strategic financial management (per the firm's official communications). The firm identifies as a clinical-stage company, and its therapeutic strategy is built entirely around bisphosphocins. These synthetic antimicrobial compounds penetrate bacterial and fungal cell membranes and cause rapid cell death through physical disruption rather than interfering with a specific metabolic pathway. This mechanism of action, according to the company's published research, means pathogens cannot easily develop resistance through single-point mutations — a structural feature that differentiates it from most antibiotics and antifungals in development. Lakewood-Amedex's lead candidate, Nu-3, has been studied in Phase II trials for diabetic foot ulcers and has been granted Orphan Drug Designation by the FDA. Other pipeline candidates target indications including cystic fibrosis-associated respiratory infections and systemic fungal infections. Scale and team information remain thin; the company has not broadly disclosed headcount, annual deployment, or external financing rounds. Its last material public update came in mid-2023, when Parkinson discussed bisphosphocin mechanisms at an academic forum focused on antimicrobial resistance. Structurally, Lakewood-Amedex illustrates the private, patent-protected single-asset-platform bet that defines earlier-stage biotech investing but is rare among family-office backed entities with perpetual capital. Its narrow focus on a novel, non-metabolic mechanism of action isolates it from the typical me-too antibiotic development found in larger pharma pipelines. The lack of disclosed fundraising rounds also raises the question of whether the company is predominantly self-funded by its principals or a single backer, which would further differentiate its governance and risk posture from institutionally syndicated drug startups.